Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 46 entries
View as:

SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins

Phase: N/A Priority: Normal
NCT ID: NCT02383953 Org: User:
Start: 05/31/15 End: 10/31/17 Due: 10/31/18

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT02529059 Org: User:
Start: 11/30/15 End: 05/31/17 Due: 05/31/18

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen

Phase: N/A Priority: Normal
NCT ID: NCT01190293 Org: User:
Start: 01/31/10 End: 03/31/12 Due: 03/31/13

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00771823 Org: User:
Start: 05/31/08 End: 11/30/08 Due: 11/30/09

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Phase: N/A Priority: Normal
NCT ID: NCT02499874 Org: User:
Start: 08/31/15 End: 10/05/17 Due: 10/05/18

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

Phase: N/A Priority: Normal
NCT ID: NCT01680536 Org: User:
Start: 11/30/12 End: 02/29/16 Due: 02/28/17

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01796431 Org: User:
Start: 03/31/13 End: 07/31/13 Due: 07/31/14

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

Phase: N/A Priority: Normal
NCT ID: NCT02098837 Org: User:
Start: 04/30/14 End: 12/04/17 Due: 12/04/18

Atripla to Raltegravir Switch Study for CNS Toxicity

Phase: N/A Priority: Normal
NCT ID: NCT01195467 Org: User:
Start: 10/31/10 End: 06/30/13 Due: 06/30/14

TMC 125 Blood Levels Study

Phase: N/A Priority: Normal
NCT ID: NCT00531323 Org: User:
Start: 09/30/07 End: 12/31/07 Due: 12/31/08

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Phase: N/A Priority: Normal
NCT ID: NCT01701882 Org: User:
Start: 09/30/12 End: 11/30/13 Due: 11/30/14

Pharmacokinetic Effect of Evotaz/Microgynon Co-administration

Phase: N/A Priority: Normal
NCT ID: NCT02697851 Org: User:
Start: 07/31/16 End: 10/31/17 Due: 10/31/18

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

Phase: N/A Priority: Normal
NCT ID: NCT01073761 Org: User:
Start: 04/30/10 End: 06/30/10 Due: 06/30/11

Men Who Have Sex With Men (MSM) Neurocog 1&2 Study

Phase: N/A Priority: Normal
NCT ID: NCT01508559 Org: User:
Start: 09/30/11 End: 12/31/13 Due: 12/31/14

Progesterone and Aminophylline for the Prevention of Preterm Labour

Phase: N/A Priority: Normal
NCT ID: NCT03152942 Org: User:
Start: 10/05/17 End: 04/30/19 Due: 04/30/20

NNRTI/PI Toxicity Switch to Darunavir Study

Phase: N/A Priority: Normal
NCT ID: NCT00765154 Org: User:
Start: 10/31/08 End: 07/31/10 Due: 07/31/11

SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02219217 Org: User:
Start: 10/31/14 End: 01/31/15 Due: 01/31/16

Raltegravir and Ezetimibe PK Study

Phase: N/A Priority: Normal
NCT ID: NCT00772551 Org: User:
Start: 06/30/08 End: 08/31/08 Due: 08/31/09

Raltegravir Insulin Sensitivity Study

Phase: N/A Priority: Normal
NCT ID: NCT00531999 Org: User:
Start: 10/31/07 End: 08/31/08 Due: 08/31/09

PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01108926 Org: User:
Start: 06/30/10 End: 10/31/10 Due: 10/31/11

Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)

Phase: N/A Priority: Normal
NCT ID: NCT02006745 Org: User:
Start: 01/31/14 End: 02/29/16 Due: 02/28/17

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

Phase: N/A Priority: Normal
NCT ID: NCT00792324 Org: User:
Start: 06/30/08 End: 08/31/09 Due: 08/31/10

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

Phase: N/A Priority: Normal
NCT ID: NCT02509195 Org: User:
Start: 08/04/15 End: 07/24/17 Due: 07/24/18

Atazanavir/Ritonavir and Zinc Pharmacokinetic Study

Phase: N/A Priority: Normal
NCT ID: NCT01475227 Org: User:
Start: 12/31/11 End: 03/31/12 Due: 03/31/13

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00765271 Org: User:
Start: 05/31/08 End: 10/31/08 Due: 10/31/09